Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 15/20 | 0.53 |
| ▸ | PPARG | P37231 | 11/20 | 0.53 |
| ▸ | PPARD | Q03181 | 9/20 | 0.53 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.40 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4575267 | 0.74 | PPARA (0.57) | PPARAPPARGPPARD | |
| SCHEMBL4575137 | 0.73 | PPARA (0.51) | PPARAPPARGPPARD | |
| SCHEMBL4575631 | 0.72 | PPARA (0.54) | PPARAPPARGPPARD | |
| SCHEMBL4575657 | 0.72 | PPARA (0.56) | PPARAPPARGPPARD | |
| SCHEMBL4575324 | 0.72 | PPARA (0.52) | PPARAPPARGPPARD | |
| SCHEMBL4575385 | 0.71 | PPARA (0.51) | PPARAPPARGPPARD | |
| SCHEMBL4576038 | 0.71 | PPARA (0.51) | PPARAPPARGPPARD | |
| SCHEMBL4575332 | 0.71 | PPARA (0.51) | PPARAPPARGPPARD | |
| SCHEMBL4575633 | 0.71 | PPARA (0.53) | PPARAPPARGPPARD | |
| SCHEMBL4574770 | 0.71 | PPARA (0.53) | PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170304241-A1 | PERK ACTIVATOR FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | KLINIKUM RECHTS DER ISAR TECHNISCHE UNIVERSITÄT MÜNCHEN (DE) | 2017-10-26 | — | — | US | claimed |
| EP-3193869-A1 | PERK ACTIVATOR FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (DE) | 2017-07-26 | — | — | EP | claimed |
| WO-2016024010-A1 | PERK ACTIVATOR FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | DEUTSCHES ZENTRUM FÜR NEURODEGENERATIVE ERKRANKUNGEN E.V. (DZNE) (DE) | 2016-02-18 | — | — | WO | claimed |
| US-10369123-B2 | Perk activator for the treatment of neurodegenerative diseases | DEUTSCHES ZENTRUM FÜR NEURODEGENERATIVE ERKRANKUNGEN E.V. (DZNE) (DE) | 2019-08-06 | — | — | US | disclosed |
| US-20170304241-A1 | PERK ACTIVATOR FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | KLINIKUM RECHTS DER ISAR TECHNISCHE UNIVERSITÄT MÜNCHEN (DE) | 2017-10-26 | — | — | US | disclosed |
| EP-3193869-A1 | PERK ACTIVATOR FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (DE) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016024010-A1 | PERK ACTIVATOR FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | DEUTSCHES ZENTRUM FÜR NEURODEGENERATIVE ERKRANKUNGEN E.V. (DZNE) (DE) | 2016-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10369123-B2 | Perk activator for the treatment of neurodegenerative diseases | ATF4, MAPT, PSEN2 | PPARA 1252/4885PPARG 1642/4885PPARD 1756/4885 |
| US-20170304241-A1 | PERK ACTIVATOR FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ATF4, MAPT, PSEN2 | PPARA 1252/4885PPARG 1642/4885PPARD 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.